Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Leukemia, Myeloid, Acute 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Primary Myelofibrosis 12Polycythemia Vera 11Myelodysplastic Syndromes 10Leukemia 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Myeloproliferative Disorders 8Recurrence 6Leukemia, Myelomonocytic, Chronic 6Hematologic Neoplasms 6Breast Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, T-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Graft vs Host Disease 5Thrombocythemia, Essential 4Leukemia, Myeloid, Chronic-Phase 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × ruxolitinib × Clear all
NCT05440942 2025-06-05

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

University of Miami

Phase 1 Completed
28 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡